[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100400557":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":41,"collaborators":7,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":7,"maxAge":7,"enrollmentInfo":52,"targetDuration":55,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":11,"whyStopped":7,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Advanced Integrative Medical Science Institute","OTHER",null,[9],{"facility":10,"status":11,"city":12,"state":13,"zip":14,"country":15,"countryCode":16,"cosmosGeoPoint":17,"geoPoint":22,"contacts":23},"AIMS Institute","RECRUITING","Seattle","Washington","98102","United States","US",{"type":18,"coordinates":19},"Point",[20,21],-122.33207,47.60621,{"lat":21,"lon":20},[24,29,32,35,38,39],{"name":25,"role":26,"phone":27,"phoneExt":7,"email":28},"Michelle Speaks, MBA","CONTACT","2064201321","mspeaks@aimsinstitute.net",{"name":30,"role":26,"phone":27,"phoneExt":7,"email":31},"Sunil K Aggarwal, MD, PhD, FAAPMR","saggarwal@aimsinstitute.net",{"name":33,"role":34,"phone":7,"phoneExt":7,"email":7},"Therry Eparwa, DNP, ARNP, FNP-BC","PRINCIPAL_INVESTIGATOR",{"name":36,"role":37,"phone":7,"phoneExt":7,"email":7},"Leanna J Standish, ND, PhD, Lac, FABNO","SUB_INVESTIGATOR",{"name":30,"role":37,"phone":7,"phoneExt":7,"email":7},{"name":40,"role":37,"phone":7,"phoneExt":7,"email":7},"Sonia S Malani, ND",{"type":42,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100400557","aims-cancer-outcomes-study-100400557",false,"NCT04495790","AIMS Cancer Outcomes Study","Advanced Integrative Oncology Treatment for Adult and Pediatric Patients With Cancer: A Prospective Outcomes Study","ACOS","Inclusion Criteria:\n\n1. A new patient coming in for a first office call (FOC) or first consultation via telemedicine with a diagnosis of cancer, or\n2. An established patient with a diagnosis of cancer receiving treatment at the AIMS Institute;\n3. If over 18 years of age are able to understand study design adequately and provide signed informed consent (IC) to enrollment;\n4. If younger than 18 years of age informed assent from the child and informed consent from a parent or guardian who is able to understand the study design adequately and provide signed informed consent for the pediatric patient;\n5. A confirmed diagnosis of cancer based on medical oncology medical records.\n\nExclusion Criteria:\n\n1. Patients not diagnosed with cancer;\n2. Telehealth patients;\n3. Cannot read or understand English well enough to read and sign the consent form and complete the questionnaires;\n4. Unwilling to participate in the AIMS Institute observational study.","ALL",{"count":53,"type":54},500,"ESTIMATED","5 Years","OBSERVATIONAL","The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect data and study outcomes for patients with cancer who receive care at AIMS Institute.",[59,60,61,62,63],"Neoplasms","Neoplasm Malignant","Advanced Cancer","Advanced Solid Tumor","Oncology",[65,66,67,68,69],"Integrative Oncology","Naturopathic Oncology","Phytomedicine","Metabolic Therapy","Immunotherapy","2023-01-30",{"date":72,"type":73},"2023-02-01","ACTUAL",{"date":75,"type":73},"2020-05-18",{"date":77,"type":54},"2030-12-31",{"name":5,"class":6},1]